1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014

Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Cognitive Impairment Associated With Schizophrenia (CIAS) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Clinical Trials by G7 Countries: Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Cognitive Impairment Associated With Schizophrenia (CIAS) 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Pfizer Inc. 32
Clinical Trial Overview of Pfizer Inc. 32
Novartis AG 33
Clinical Trial Overview of Novartis AG 33
Merck and Co., Inc. 34
Clinical Trial Overview of Merck and Co., Inc. 34
AbbVie Inc. 35
Clinical Trial Overview of AbbVie Inc. 35
Takeda Pharmaceutical Company Limited 36
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 36
Saniona AB 37
Clinical Trial Overview of Saniona AB 37
Johnson and Johnson 38
Clinical Trial Overview of Johnson and Johnson 38
GlaxoSmithKline plc 39
Clinical Trial Overview of GlaxoSmithKline plc 39
Clinical Trial Overview of Top Institutes / Government 40
VA Greater Los Angeles Healthcare Center 40
Clinical Trial Overview of VA Greater Los Angeles Healthcare Center 40
Hamamatsu University School of Medicine 41
Clinical Trial Overview of Hamamatsu University School of Medicine 41
Bronx Veterans Medical Research Foundation 42
Clinical Trial Overview of Bronx Veterans Medical Research Foundation 42
Mashhad University of Medical Sciences 43
Clinical Trial Overview of Mashhad University of Medical Sciences 43
St. Marianna University School of Medicine 44
Clinical Trial Overview of St. Marianna University School of Medicine 44
Yale University 45
Clinical Trial Overview of Yale University 45
Indiana University 46
Clinical Trial Overview of Indiana University 46
Central South University 47
Clinical Trial Overview of Central South University 47
University of Southern Denmark 48
Clinical Trial Overview of University of Southern Denmark 48
Northwestern University 49
Clinical Trial Overview of Northwestern University 49
Five Key Clinical Profiles 50
Appendix 71
Abbreviations 71
Definitions 71
Research Methodology 72
Secondary Research 72
About GlobalData 73
Contact Us 73
Disclaimer 73
Source 73

List of Tables
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 32
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 33
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 34
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 35
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 36
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Saniona AB, 2014* 37
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 38
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 39
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by VA Greater Los Angeles Healthcare Center, 2014* 40
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 41
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bronx Veterans Medical Research Foundation, 2014* 42
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mashhad University of Medical Sciences, 2014* 43
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Marianna University School of Medicine, 2014* 44
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2014* 45
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University, 2014* 46
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Central South University, 2014* 47
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Southern Denmark, 2014* 48
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 49

List of Figures
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 11
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 72

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.